Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$1.6 - $2.82 $119,747 - $211,054
74,842 New
74,842 $145,000
Q1 2020

May 15, 2020

SELL
$1.91 - $4.08 $83,203 - $177,732
-43,562 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.71 - $4.91 $30,929 - $213,889
43,562 New
43,562 $195,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.